{"id":"cmr53morq0005coegikl8g2l8","slug":"ozempic-vs-victoza)","title":"Ozempic vs Victoza","shortAnswer":"Ozempic and Victoza are both GLP-1 receptor agonists, but Ozempic is dosed weekly while Victoza requires daily injections, and Ozempic has demonstrated superior weight loss results (average 15% body weight reduction vs. 5-6% for Victoza) in clinical trials.","keyDifferences":[{"label":"Injection Frequency","winner":"a","entityAValue":"Once weekly","entityBValue":"Once daily"},{"label":"Average Weight Loss","winner":"a","entityAValue":"15% body weight (SUSTAIN-6 trial)","entityBValue":"5-6% body weight"},{"label":"FDA Indication for Type 2 Diabetes","winner":"tie","entityAValue":"Yes, approved 2017","entityBValue":"Yes, approved 2010"},{"label":"GLP-1 Agonist Class","winner":"a","entityAValue":"Long-acting (semaglutide)","entityBValue":"Short-acting (liraglutide)"},{"label":"Cardiovascular Outcome Trial","winner":"a","entityAValue":"SUSTAIN-6: 26% reduction in cardiovascular events","entityBValue":"LEADER: 13% reduction in cardiovascular events"},{"label":"Maximum Weekly Dose","winner":"a","entityAValue":"2.4 mg","entityBValue":"1.8 mg daily (12.6 mg weekly equivalent)"},{"label":"Time to Market","winner":"b","entityAValue":"2017 (7 years newer)","entityBValue":"2010"}],"verdict":"Choose Ozempic if you prioritize maximum weight loss, need better cardiovascular protection, and prefer weekly dosing for convenience and compliance. Choose Victoza if you have a longer history with the medication class, prefer a more conservative approach for your first GLP-1 therapy, or have insurance limitations, though Ozempic's superior efficacy makes it the preferred first-line option for most patients with type 2 diabetes.","category":"health","entities":[{"id":"cmqpzg00v00bq10nsogj9y471","slug":"ozempic-semaglutide","name":"Ozempic (semaglutide)","shortDesc":"Weekly injectable GLP-1 receptor agonist for type 2 diabetes with potent weight loss and cardiovascular benefits.","imageUrl":null,"entityType":"product","position":0,"pros":["Once-weekly injection increases compliance vs. daily alternatives","15% average body weight reduction in SUSTAIN-6 clinical trial","26% relative reduction in major cardiovascular events (SUSTAIN-6)","Effective A1C reduction to <7% in majority of users","Pre-filled pen device with simple injection mechanism"],"cons":["Higher cost with average monthly prices $900-$1,300 before insurance","Higher incidence of gastrointestinal side effects (nausea 25-39% of users)","Risk of pancreatitis and C-cell thyroid tumors in animal studies (black box warning applies to GLP-1 class)"],"bestFor":"Patients with type 2 diabetes seeking maximum weight loss and cardiovascular protection who prioritize convenient once-weekly dosing."},{"id":"cmqsgo0rz007gx8imqs9m92wm","slug":"victoza-liraglutide","name":"Victoza (liraglutide)","shortDesc":"Daily injectable GLP-1 receptor agonist for type 2 diabetes with established long-term safety record.","imageUrl":null,"entityType":"product","position":1,"pros":["FDA approved since 2010 with 14+ years of real-world safety data","13% relative reduction in major cardiovascular events (LEADER trial)","5-6% average body weight reduction in clinical trials","Lower cost in many insurance plans (average $600-$900 monthly)","Proven effective for both type 2 diabetes and chronic weight management (Saxenda formulation)"],"cons":["Requires daily injections reducing compliance vs. weekly alternatives","Modest weight loss compared to newer long-acting GLP-1 agonists","Gastrointestinal side effects present in 20-30% of users, though potentially less severe than Ozempic"],"bestFor":"Patients new to GLP-1 therapy seeking established safety data, those unable to afford newer alternatives, or patients with moderate weight loss goals who tolerate daily injections."}],"attributes":[{"id":"cmmxr7qxj01j5lh9ek2ewsqjp","slug":"average-weight-loss","name":"Average Weight Loss","unit":"%","category":"Efficacy","dataType":"text","higherIsBetter":true,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"15%","valueNumber":15,"valueBoolean":null}]},{"id":"cmqpzg01w00c510nszm8x058y","slug":"dosing-frequency","name":"Dosing Frequency","unit":"times per week","category":"Administration","dataType":"number","higherIsBetter":false,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"1x weekly","valueNumber":1,"valueBoolean":null}]},{"id":"cmqpzg02500cb10nsc3v1vbh2","slug":"time-to-maximum-dose","name":"Time to Maximum Dose","unit":"weeks","category":"Efficacy","dataType":"number","higherIsBetter":false,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"4 weeks","valueNumber":4,"valueBoolean":null}]},{"id":"cmqpzg02m00cn10nshzd16hr3","slug":"fda-approval-year-for-weight-loss-","name":"FDA Approval Year (for weight loss)","unit":"year","category":"Clinical History","dataType":"number","higherIsBetter":false,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"2021 (Wegovy)","valueNumber":2021,"valueBoolean":null}]},{"id":"cmqpzg02u00ct10ns4tcc8dju","slug":"average-monthly-cost-uninsured-","name":"Average Monthly Cost (Uninsured)","unit":"USD","category":"Cost","dataType":"number","higherIsBetter":false,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"$1,100","valueNumber":1100,"valueBoolean":null,"winner":false},{"entityId":"cmqsgo0rz007gx8imqs9m92wm","valueText":"$750","valueNumber":750,"valueBoolean":null,"winner":true}]},{"id":"cmqpzg03900d510nsidl8plq9","slug":"clinical-trial-duration","name":"Clinical Trial Duration","unit":"weeks","category":"Study Design","dataType":"number","higherIsBetter":null,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"68 weeks (STEP)","valueNumber":68,"valueBoolean":null}]},{"id":"cmn900hxl000t10cf4rtryhnp","slug":"fda-approval-year","name":"FDA Approval Year","unit":null,"category":"Regulatory","dataType":"number","higherIsBetter":false,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"2017","valueNumber":2017,"valueBoolean":null}]},{"id":"cmn900hws000h10cfm7vpikaz","slug":"maximum-weekly-dose","name":"Maximum Weekly Dose","unit":"mg","category":"Dosing","dataType":"number","higherIsBetter":true,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"2.0 mg","valueNumber":2,"valueBoolean":null}]},{"id":"cmqqtedeq00k7wvslcoium7wl","slug":"hba1c-reduction-type-2-diabetes-","name":"HbA1c Reduction (Type 2 Diabetes)","unit":"%","category":"Clinical Efficacy","dataType":"number","higherIsBetter":true,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"1.5-1.8%","valueNumber":1.65,"valueBoolean":null}]},{"id":"cmqqtedf000kdwvslabqfxr2p","slug":"average-weight-loss-in-pivotal-trial","name":"Average Weight Loss in Pivotal Trial","unit":"lbs","category":"Clinical Efficacy","dataType":"number","higherIsBetter":true,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"4-6 lbs (secondary outcome)","valueNumber":5,"valueBoolean":null}]},{"id":"cmqpzg02e00ch10ns2c42jedn","slug":"nausea-incidence-rate","name":"Nausea Incidence Rate","unit":"%","category":"Safety","dataType":"number","higherIsBetter":false,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"25-40%","valueNumber":32.5,"valueBoolean":null}]},{"id":"cmqqtedfg00kpwvslyho1zku4","slug":"insurance-coverage-rate-for-primary-indication","name":"Insurance Coverage Rate for Primary Indication","unit":"%","category":"Access","dataType":"number","higherIsBetter":true,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"85% (diabetes)","valueNumber":85,"valueBoolean":null}]},{"id":"cmqqtedfo00kvwvslq37bfgu6","slug":"cvot-cardiovascular-risk-reduction","name":"CVOT Cardiovascular Risk Reduction","unit":"%","category":"Clinical Benefit","dataType":"number","higherIsBetter":true,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"26%","valueNumber":26,"valueBoolean":null}]},{"id":"cmqqtedfw00l1wvslgj51ubzg","slug":"trial-duration-for-primary-endpoint","name":"Trial Duration for Primary Endpoint","unit":"weeks","category":"Evidence","dataType":"number","higherIsBetter":true,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"52 weeks (SUSTAIN-6)","valueNumber":52,"valueBoolean":null}]},{"id":"cmqsgo0sz007tx8imbg689kva","slug":"maximum-weight-loss-at-highest-approved-dose","name":"Maximum Weight Loss at Highest Approved Dose","unit":"%","category":"Efficacy","dataType":"number","higherIsBetter":true,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"22%","valueNumber":22,"valueBoolean":null,"winner":true},{"entityId":"cmqsgo0rz007gx8imqs9m92wm","valueText":"6%","valueNumber":6,"valueBoolean":null,"winner":false}]},{"id":"cmqsgo0tp007zx8im1y3ik8ja","slug":"a1c-reduction-average-","name":"A1C Reduction (Average)","unit":"mmol/mol","category":"Efficacy","dataType":"number","higherIsBetter":true,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"1.5-1.8%","valueNumber":1.65,"valueBoolean":null,"winner":true},{"entityId":"cmqsgo0rz007gx8imqs9m92wm","valueText":"1.2-1.5%","valueNumber":1.35,"valueBoolean":null,"winner":false}]},{"id":"cmqsgo0vy0085x8imnqok1ww8","slug":"half-life-duration","name":"Half-Life Duration","unit":"hours","category":"Pharmacology","dataType":"number","higherIsBetter":true,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"168 hours (7 days)","valueNumber":168,"valueBoolean":null,"winner":true},{"entityId":"cmqsgo0rz007gx8imqs9m92wm","valueText":"13 hours","valueNumber":13,"valueBoolean":null,"winner":false}]},{"id":"cmqsgo0w6008bx8im584h62yv","slug":"average-monthly-cost-without-insurance-","name":"Average Monthly Cost (Without Insurance)","unit":"USD","category":"Cost","dataType":"number","higherIsBetter":false,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"$1,100","valueNumber":1100,"valueBoolean":null,"winner":false},{"entityId":"cmqsgo0rz007gx8imqs9m92wm","valueText":"$950","valueNumber":950,"valueBoolean":null,"winner":true}]},{"id":"cmqsgo0we008hx8imukbh0r8r","slug":"time-to-reach-steady-state","name":"Time to Reach Steady State","unit":"weeks","category":"Pharmacology","dataType":"number","higherIsBetter":false,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"4-5 weeks","valueNumber":4.5,"valueBoolean":null,"winner":false},{"entityId":"cmqsgo0rz007gx8imqs9m92wm","valueText":"1-2 weeks","valueNumber":1.5,"valueBoolean":null,"winner":true}]},{"id":"cmqsgo0wm008nx8imhwwj9da2","slug":"gi-side-effect-incidence-rate","name":"GI Side Effect Incidence Rate","unit":"%","category":"Safety","dataType":"number","higherIsBetter":false,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"32%","valueNumber":32,"valueBoolean":null,"winner":false},{"entityId":"cmqsgo0rz007gx8imqs9m92wm","valueText":"26%","valueNumber":26,"valueBoolean":null,"winner":true}]},{"id":"cmqsgo0wu008tx8imsi8a862a","slug":"years-on-market","name":"Years on Market","unit":"years","category":"Experience","dataType":"number","higherIsBetter":true,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"11 years (since 2013)","valueNumber":11,"valueBoolean":null,"winner":false},{"entityId":"cmqsgo0rz007gx8imqs9m92wm","valueText":"15 years (since 2009)","valueNumber":15,"valueBoolean":null,"winner":true}]},{"id":"cmqmnzuku007xd71w4nc7qkq7","slug":"injection-frequency","name":"Injection Frequency","unit":null,"category":"Convenience & Dosing","dataType":"number","higherIsBetter":false,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"Once weekly","valueNumber":1,"valueBoolean":null,"winner":true},{"entityId":"cmqsgo0rz007gx8imqs9m92wm","valueText":"Once daily","valueNumber":7,"valueBoolean":null,"winner":false}]},{"id":"cmr53mosj000hcoeghsf8i9t2","slug":"average-body-weight-loss","name":"Average Body Weight Loss","unit":"%","category":"Efficacy","dataType":"number","higherIsBetter":true,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"15%","valueNumber":15,"valueBoolean":null,"winner":true},{"entityId":"cmqsgo0rz007gx8imqs9m92wm","valueText":"5.6%","valueNumber":5.6,"valueBoolean":null,"winner":false}]},{"id":"cmqpzg03100cz10nsjbgyegya","slug":"cardiovascular-event-reduction","name":"Cardiovascular Event Reduction","unit":"%","category":"Safety & Outcomes","dataType":"number","higherIsBetter":true,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"26% (SUSTAIN-6)","valueNumber":26,"valueBoolean":null,"winner":true},{"entityId":"cmqsgo0rz007gx8imqs9m92wm","valueText":"13% (LEADER)","valueNumber":13,"valueBoolean":null,"winner":false}]},{"id":"cmqvq90um008ltyokq13z9mrl","slug":"maximum-approved-dose","name":"Maximum Approved Dose","unit":"mg","category":"Dosing","dataType":"number","higherIsBetter":null,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"2.4 mg weekly","valueNumber":2.4,"valueBoolean":null},{"entityId":"cmqsgo0rz007gx8imqs9m92wm","valueText":"1.8 mg daily","valueNumber":1.8,"valueBoolean":null}]},{"id":"cmr53motd0015coegeh5tekof","slug":"years-since-fda-approval","name":"Years Since FDA Approval","unit":"years","category":"Market History","dataType":"number","higherIsBetter":false,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"7 years (2017)","valueNumber":7,"valueBoolean":null,"winner":true},{"entityId":"cmqsgo0rz007gx8imqs9m92wm","valueText":"16 years (2010)","valueNumber":16,"valueBoolean":null,"winner":false}]},{"id":"cmr53motk001bcoegcxwjyyrt","slug":"nausea-incidence-in-trials","name":"Nausea Incidence in Trials","unit":"%","category":"Safety","dataType":"number","higherIsBetter":false,"values":[{"entityId":"cmqpzg00v00bq10nsogj9y471","valueText":"25-39%","valueNumber":32,"valueBoolean":null,"winner":false},{"entityId":"cmqsgo0rz007gx8imqs9m92wm","valueText":"20-30%","valueNumber":25,"valueBoolean":null,"winner":true}]}],"faqs":[{"question":"Which medication causes more weight loss?","answer":"Ozempic produces substantially more weight loss, with clinical trials (SUSTAIN-6) showing 15% average body weight reduction compared to Victoza's 5-6% reduction. This difference is significant enough that many endocrinologists now prefer Ozempic as first-line therapy for patients whose primary goal includes weight management alongside diabetes control."},{"question":"Is Ozempic better for your heart?","answer":"Yes, Ozempic shows superior cardiovascular benefits with a 26% reduction in major adverse cardiovascular events in the SUSTAIN-6 trial versus Victoza's 13% reduction in the LEADER trial. Both are GLP-1 agonists with cardiovascular benefits, but Ozempic's longer-acting formulation and higher dose potential contribute to more robust outcomes."},{"question":"Why would someone still choose Victoza over Ozempic?","answer":"Victoza remains appropriate for patients who: (1) have established tolerance to the medication with 16 years of clinical data, (2) face insurance barriers or cost concerns (typically $300-400 cheaper per month), (3) prefer a more gradual/conservative approach as a first GLP-1 therapy, or (4) have difficulty tolerating once-weekly dosing schedules. However, most new patients now initiate Ozempic due to superior efficacy."},{"question":"Can you switch from Victoza to Ozempic?","answer":"Yes, switching is common and typically straightforward. Since both are GLP-1 receptor agonists, the mechanism of action is identical. Your doctor will discontinue Victoza and start Ozempic at the appropriate dose (usually 0.25-0.5 mg weekly), gradually titrating up. Gastrointestinal side effects may temporarily increase during the transition as Ozempic is more potent."},{"question":"Are there serious side effects shared by both medications?","answer":"Both carry black box warnings for potential C-cell thyroid tumors (based on rodent studies) and pancreatitis risk. Both cause gastrointestinal side effects (nausea, vomiting, constipation, diarrhea) in 20-40% of users during the titration phase. Neither should be used if you have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2."}],"relatedComparisons":[{"slug":"ozempic-vs-victoza","title":"Ozempic vs Victoza","category":"health"},{"slug":"ozempic-vs-saxenda","title":"Ozempic vs Saxenda","category":"health"},{"slug":"ozempic-vs-zepbound","title":"Ozempic vs Zepbound","category":"health"},{"slug":"yoga-vs-pilates","title":"Yoga vs Pilates","category":"health"},{"slug":"ibuprofen-vs-acetaminophen","title":"Ibuprofen vs Acetaminophen","category":"health"},{"slug":"invisalign-vs-braces","title":"Invisalign vs Braces","category":"health"},{"slug":"lasik-vs-prk","title":"LASIK vs PRK","category":"health"},{"slug":"whey-protein-vs-casein-protein","title":"Whey Protein vs Casein Protein","category":"health"},{"slug":"crossfit-vs-gym-training","title":"CrossFit vs Gym Training","category":"health"},{"slug":"flu-shot-vs-covid-vaccine","title":"Flu Shot vs COVID Vaccine","category":"health"},{"slug":"organic-food-vs-non-organic-food","title":"Organic Food vs Non-Organic Food","category":"health"},{"slug":"therapy-vs-medication","title":"Therapy vs Medication","category":"health"}],"relatedBlogPosts":[{"slug":"keto-vs-carnivore-vs-paleo-which-diet-works-best-in-2026","title":"Keto vs Carnivore vs Paleo: Which Diet Works Best in 2026?","excerpt":"Choosing between keto, carnivore, and paleo diets can be overwhelming. We break down the key differences, benefits, and drawbacks of each approach to help you find the best diet for your 2026 health goals.","category":"health"}],"metadata":{"metaTitle":"Ozempic vs Victoza 2026: Which GLP-1 Is Better?","metaDescription":"Compare Ozempic vs Victoza: weekly vs daily injections, 15% vs 5.6% weight loss, cost, and cardiovascular benefits for type 2 diabetes.","publishedAt":"2026-07-03T15:39:20.937Z","updatedAt":"2026-07-03T15:39:21.447Z","isAutoGenerated":true,"isHumanReviewed":false,"viewCount":0}}